{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:40Z","timestamp":1779196300418,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) have become a cornerstone of therapy in the management ovarian cancer and other cancers. PARPi are associated with significant toxicities and management strategies are primarily founded on clinical trial experience. This study aimed to provide an evaluation of patients receiving PARPi therapy within an academic health-system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational study of adult patients with gynecologic malignancy was conducted at the University of Pennsylvania Health System. Data was collected on patients prescribed a PARPi between December 2014 and October 2019. The primary endpoint was the status of PARPi therapy at the end of the study period. Key secondary endpoints included toxicity management strategies, time to discontinuation due to toxicity, progression free survival (PFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 85 patients included, 45 (53%) received olaparib, 24 (28%) niraparib, and 16 (19%) rucaparib. Twenty-nine patients (34%) continued on therapy, 15 (18%) discontinued due to toxicity, and 41 (48%) discontinued due to progression. Fifty-one percent of patients required a dose reduction due to toxicities. The median time to discontinuation due to toxicity was 69\u2009days (9-353). Median PFS was 181\u2009days (9-365) and median OS was 338\u2009days (9-365).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PARPi therapy is associated with numerous toxicities that are best managed through a multi-modal approach. Importantly, about half the patients in the current study required a dose reduction. Overall, this observational study outlines the incidence of PARPi toxicities and reviews potential management strategies, further guiding practitioners in an area with limited real-world experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211024728","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T03:44:24Z","timestamp":1623901464000},"page":"1102-1110","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-7766","authenticated-orcid":false,"given":"Rachel V","family":"Hatch","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweta U","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Cambareri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Uritsky","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lainie P","family":"Martin","sequence":"additional","affiliation":[{"name":"Hematology Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_3_2_3_2","first-page":"549","article-title":"Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: a drug class review","volume":"43","author":"Ringley JT","year":"2018","unstructured":"Ringley JT, Moore DC, Patel J, et\u00a0al. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: a drug class review. P T 2018; 43: 549\u2013556.","journal-title":"P T"},{"key":"e_1_3_2_4_2","unstructured":"Howlader N Noone A Krapcho M et\u00a0al. SEER cancer statistics review 1975-2014 National Cancer Institute https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/ (2017 accessed 20 August 2019)."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.05.022"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02960"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834011417039"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_2_10_2","volume-title":"Lynparza (package insert)","author":"AstraZeneca Pharmaceuticals","year":"2020","unstructured":"AstraZeneca Pharmaceuticals. Lynparza (package insert). Wilmington, DE: AstraZeneca Pharmaceuticals, 2020."},{"key":"e_1_3_2_11_2","volume-title":"Rubraca (package insert)","author":"Clovis Oncology","year":"2020","unstructured":"Clovis Oncology. Rubraca (package insert). Boulder, CO: Clovis Oncology, 2020."},{"key":"e_1_3_2_12_2","volume-title":"Zejula (package insert)","author":"Tesaro I.","year":"2020","unstructured":"Tesaro I. Zejula (package insert). Waltham, MA: Tesaro, Inc., 2020."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30786-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0268"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.01.011"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0604-z"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0394"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3"},{"key":"e_1_3_2_25_2","unstructured":"Common terminology criteria for adverse events (CTCAE). Version 5.0. Bethesda MD: National Institute of Health: National Cancer Institute 2017."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30559-9"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.12.020"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy181"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.01.010"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211024728","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211024728","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211024728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:19Z","timestamp":1779194239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211024728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552211024728"],"URL":"https:\/\/doi.org\/10.1177\/10781552211024728","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}